Historic Shift: Trump Moves Medical Marijuana to Schedule III

Editor's Brief

Thursday, April 24, 2026 will be remembered as a watershed moment in American cannabis history. The Trump administration officially reclassified state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act — a move that sends shockwaves through every corner of the industry. Markets reacted, states scrambled to issue guidance, and consumers across the country asked the same question: what does this actually change?

The short answer is: a lot, but not everything. Recreational cannabis remains Schedule I. Federal prohibition is not over. But for patients, businesses, researchers, and investors, the ground has meaningfully shifted. Today's digest breaks it all down.

Top Story

Medical Marijuana Moves to Schedule III — Here's What It Really Means

Under an order from Acting Attorney General Todd Blanche, the Trump administration officially reclassified FDA-approved marijuana products and cannabis sold under qualifying state medical marijuana licenses to Schedule III of the Controlled Substances Act. A new administrative hearing has been set for June 29, 2026 to continue the broader rescheduling review process. This is not full legalization — but it is the most significant federal cannabis policy shift in decades.

For the cannabis industry, the most immediate win is relief from Section 280E of the tax code, which previously barred cannabis businesses from deducting ordinary business expenses. Federal officials confirmed that new tax guidance is coming as rescheduling takes effect. That change alone could be transformative for businesses that have been operating at razor-thin margins while paying effective tax rates north of 70%.

For patients and consumers, the reclassification signals federal acknowledgment that cannabis has accepted medical use — a recognition long denied under Schedule I. Critically, recreational cannabis and adult-use markets remain in legal limbo. States like Colorado, Massachusetts, and Nevada are already issuing guidance on how their industries should proceed, reflecting the patchwork complexity that still defines U.S. cannabis law.

Watch closely for two things in coming weeks: how the IRS implements new tax guidance, and whether the June 29 hearing accelerates a path toward full descheduling. The AP reports this reclassification may only be Trump's first step — leaving the door open for further federal action that could reshape the industry entirely.

Policy & Legalization

Trump Pushes Congress on Hemp-Derived CBD

Simultaneously with the rescheduling announcement, President Trump called on Congress to protect full-spectrum CBD products derived from hemp. Without legislative action, a provision in current law threatens to federally recriminalize hemp-derived CBD in November 2026. The window for Congress to act is narrow, and industry groups are watching closely.

States React: Colorado, Nevada, Massachusetts Weigh In

Industry leaders in Colorado expressed cautious enthusiasm, noting that while rescheduling is historic, the lack of federal legalization leaves significant regulatory uncertainty. Nevada's cannabis regulators issued a joint release advising their industry on how to proceed following reclassification. Massachusetts operators welcomed the move but flagged ongoing concerns about interstate commerce restrictions that remain firmly in place.

Marijuana Gun Rights Case Unaffected, DOJ Says

The Department of Justice clarified that the rescheduling does not impact pending cases involving marijuana and federal gun rights — a significant note for cannabis users in states where carry laws intersect with federal drug status. The legal gray zone for cannabis consumers and firearms remains unresolved. Advocacy groups say this underscores why full descheduling, not rescheduling, is the only real solution.

Business & Markets

Markets Respond as Industry Eyes 280E Relief

Bloomberg reports U.S. cannabis restrictions have eased in a move described as a "lift to the ailing industry." Canopy Growth stock saw notable movement Thursday as investors digested the implications of Schedule III status. CNBC published two separate explainers on what rescheduling means for both investors and the drug itself — a sign of how broad the market interest has become.

Minnesota Teen Use Drops Sharply — A Data Win for Legalization Advocates

New data from the 2025 Minnesota Student Survey shows past-year cannabis use among 11th graders nearly halved from 25.2% in 2013 to 12.7% in 2025. Use among 9th graders fell proportionally as well. This directly undercuts the oft-cited concern that legalization increases youth access — and gives advocates powerful ammunition in ongoing state-level debates.

Iowa Democrat Releases Adult-Use Legalization Plan

Iowa gubernatorial candidate Rob Sand unveiled an adult-use cannabis legalization proposal framed as a fiscal solution to the state's nearly $1.4 billion budget gap. His pitch: Iowans are already driving across state lines to buy cannabis legally, taking tax dollars with them. The economic framing reflects a broader 2026 campaign trend of treating cannabis legalization as a budget issue, not just a civil liberties one.

Science & Cultivation

Your Plastic Pots May Be Sabotaging Your Grow

High Times published a deep dive into why plastic pots could be silently limiting your yields. Root-bound plants — common in plastic containers — restrict growth, reduce nutrient uptake, and can cause heat stress in summer grows. Fabric pots promote air pruning of roots, encouraging a denser, more efficient root structure that translates directly into bigger canopy and heavier harvests.

Scientists Engineer Psychedelic Compounds in Tobacco Plants

In a remarkable biotech development, researchers have rewired tobacco plants to produce psychedelic compounds including psilocybin and DMT. While this is not a cannabis story per se, it signals a broader shift in how we think about plant-based medicine production. The implications for biosynthetic cannabinoid and terpene production are significant — what works in tobacco may eventually translate to cannabis breeding and extraction science.

How to Vape Correctly — A Practical Primer

With rescheduling bringing new consumers into the medical cannabis fold, The Fresh Toast published a timely guide on proper vaping technique for beginners using store-bought pens. Key tips include low-temperature draws for flavor preservation and avoiding overheating cartridges, which degrades cannabinoids and terpenes. A good read to share with newly minted medical patients.

Crime & Enforcement

Drug Busts Continue Despite Federal Policy Shift

In Somerset, Australia, two individuals were charged with drug trafficking after police seized 2 kilograms of cannabis. Separately, hundreds of cannabis plants were confiscated in another Australian bust covered by 2HD. These cases are a reminder that rescheduling in the U.S. has zero bearing on enforcement in other jurisdictions — and that even in legal markets, unlicensed cultivation carries serious criminal exposure.

Culture & Community

Germany's Cannabis Clubs: Together but Alone

High Times explored the paradox of Germany's cannabis social clubs, where members can grow together legally — but must consume alone. Strict rules prohibit on-site smoking, creating a strange social dynamic that undercuts the communal spirit the clubs were designed to foster. It's a cautionary tale about how regulatory design can hollow out the culture it purports to support.

NECANN Boston Opens Its Doors Today

The New England Cannabis Convention returns to Boston's Hynes Convention Center today and tomorrow, April 24–25. The event serves as the annual gathering point for East Coast cannabis professionals as the region's market continues to mature. If you're in the industry and anywhere near Boston, this is the room to be in today.

What This Means for Growers

• Rescheduling won't touch your home grow directly — state laws govern personal cultivation rights, and those haven't changed. But a friendlier federal stance could accelerate state-level reform in holdout states.
• Research funding should increase — Schedule III status removes key barriers to studying cannabis, meaning better data on strains, cannabinoids, and cultivation practices could emerge over the next few years.
• Ditch the plastic pots now. Today's High Times piece on fabric pots is genuinely actionable. Root-bound plants in plastic are one of the most common and easily fixed yield killers in home grows.
• Hemp-derived CBD and terpene products remain in regulatory limbo — if you use hemp-based inputs or supplements in your grow operation, watch the November 2026 deadline Congress is being pressured to address.
• Legal market prices may stabilize or drop — 280E tax relief for licensed producers could ease cost pressures that have artificially inflated dispensary prices, eventually affecting the competitive landscape for home growers supplying personal-use states.

Quick Links

Full source links are listed below this article.